secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001641172-25-026931
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo
--------------------------------------------------------------------------------

- New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.
- Telomir-1 outperformed rapamycin and chemotherapy in reactivating the master tumor suppressor CDKN2A.
- Findings build on prior STAT1 data, supporting Telomir-1 as a broad-spectrum DNA methylation reset therapy.
- Company advancing pre-IND program with CMC and IND-enabling studies toward first IND submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/0001641172-25-026931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225026931/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer